Biogen (BIIB) Tops Q3 EPS by 37c; cuts EPS forecast
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Join SI Premium – FREE
(Updated - November 8, 2023 7:04 AM EST)
Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.36, $0.37 better than the analyst estimate of $3.99. Revenue for the quarter came in at $2.53 billion versus the consensus estimate of $2.39 billion.
GUIDANCE:
Biogen sees FY2023 EPS of $14.50-$15.00, saw $15.00-16.00,
- Reflecting ~$0.75 of dilution from Reata acquisition which closed September 26, 2023
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
- 8x8, Inc. (EGHT) Reports In-Line Q2 EPS
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
